Caribou Biosciences Q3 net loss $10M, cash $396.7M; pipeline advances with CB-010, CB-011, CB-012

Caribou Biosciences, Inc.

2023-Q3 EPS reported -$0.98 revenue$30,919,000

Net loss of $10.0M for Q3 2023 vs $26.6M in Q3 2022; revenue $23.7M (incl. $21.5M from AbbVie termination).
Cash, equivalents, and marketable securities $396.7M as of Sept 30, 2023; funding expected into Q4 2025.
CB-010 ANTLER trial dose expansion continues; FDA meeting for pivotal trial planned, data H1 2024.
CB-011 CaMMouflage trial at dose level 2; CB-012 IND cleared, enrollment expected by mid-2024.
Completed $134.4M follow-on offering and received $25M Pfizer investment in Q3 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Caribou Biosciences, Inc. reported third quarter of 2023 results: revenue $23.7 million.

Period: third quarter of 2023
Revenue: $23.7 million
Result: reported results

Exact text from the filing

will be sufficient to fund its current operating plan into Q4 2025. Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $23.7 million for the three months ended September 30, 2023, compared to $3.3 2 million for the same period 2022. The increase was primarily due to $21.5 million in revenue recognized under

View on SEC.gov

Browse all earnings releases →

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001619856-23-000123

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.